Patents by Inventor Martin B. Wax

Martin B. Wax has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OCULAR FORMULATIONS FOR DRUG-DELIVERY AND PROTECTION OF THE ANTERIOR SEGMENT OF THE EYE
    Publication number: 20210275501
    Abstract: The present application relates to topical formulations comprising Compound-I or its free base, and a second active agent selected from nicotinic acid, nicotinamide, and vitamin K, and a combination thereof, for treating ocular neovascularization. The present application also relates to pharmaceutical compositions comprising particles of Compound-I or its free base, and suspension formulations comprising the particle compositions of Compound-I or its free base.
    Type: Application
    Filed: October 13, 2020
    Publication date: September 9, 2021
    Inventors: David P. BINGAMAN, Paul G. CHANEY, Martin B. WAX
  • OCULAR FORMULATIONS FOR DRUG-DELIVERY TO THE POSTERIOR SEGMENT OF THE EYE
    Publication number: 20210196690
    Abstract: The present invention relates to topical formulations comprising a compound of the following formula: for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w/v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and/or the choroid.
    Type: Application
    Filed: March 12, 2021
    Publication date: July 1, 2021
    Inventors: David P. BINGAMAN, Paul G. CHANEY, Martin B. WAX
  • OCULAR FORMULATIONS FOR DRUG-DELIVERY AND PROTECTION OF THE ANTERIOR SEGMENT OF THE EYE
    Publication number: 20190314343
    Abstract: The present application relates to topical formulations comprising Compound-I or its free base, and a second active agent selected from nicotinic acid, nicotinamide, and vitamin K, and a combination thereof, for treating ocular neovascularization. The present application also relates to pharmaceutical compositions comprising particles of Compound-I or its free base, and suspension formulations comprising the particle compositions of Compound-I or its free base.
    Type: Application
    Filed: November 13, 2018
    Publication date: October 17, 2019
    Inventors: David P. BINGAMAN, Paul G. CHANEY, Martin B. WAX
  • OCULAR FORMULATIONS FOR DRUG-DELIVERY TO THE POSTERIOR SEGMENT OF THE EYE
    Publication number: 20190247368
    Abstract: The present invention relates to topical formulations comprising a compound of the following formula: for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w/v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and/or the choroid.
    Type: Application
    Filed: April 23, 2019
    Publication date: August 15, 2019
    Inventors: David P. BINGAMAN, Paul G. CHANEY, Martin B. WAX
  • OCULAR FORMULATIONS FOR DRUG-DELIVERY TO THE POSTERIOR SEGMENT OF THE EYE
    Publication number: 20190240201
    Abstract: The present invention relates to topical formulations comprising a compound of the following formula: for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w/v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and/or the choroid.
    Type: Application
    Filed: April 16, 2019
    Publication date: August 8, 2019
    Inventors: David P. BINGAMAN, Paul G. CHANEY, Martin B. WAX
  • OCULAR FORMULATIONS FOR DRUG-DELIVERY TO THE POSTERIOR SEGMENT OF THE EYE
    Publication number: 20190183864
    Abstract: The present invention relates to topical formulations comprising a compound of the following formula: for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w/v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and/or the choroid.
    Type: Application
    Filed: July 23, 2018
    Publication date: June 20, 2019
    Inventors: David P. BINGAMAN, Paul G. CHANEY, Martin B. WAX
  • Ocular formulations for drug-delivery to the posterior segment of the eye
    Patent number: 10307404
    Abstract: The present invention relates to topical formulations comprising a compound of the following formula: for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w/v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and/or the choroid.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: June 4, 2019
    Assignee: PanOptica, Inc.
    Inventors: David P. Bingaman, Paul G. Chaney, Martin B. Wax
  • Ocular formulations for drug-delivery and protection of the anterior segment of the eye
    Patent number: 10183014
    Abstract: The present application relates to topical formulations comprising Compound-I or its free base, and a second active agent selected from nicotinic acid, nicotinamide, and vitamin K, and a combination thereof, for treating ocular neovascularization. The present application also relates to pharmaceutical compositions comprising particles of Compound-I or its free base, and suspension formulations comprising the particle compositions of Compound-I or its free base.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: January 22, 2019
    Inventors: David P. Bingaman, Paul G. Chaney, Martin B. Wax
  • Ocular formulations for drug-delivery to the posterior segment of the eye
    Patent number: 10092549
    Abstract: The present invention relates to topical formulations comprising a compound of the following formula: for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w/v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and/or the choroid.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 9, 2018
    Assignee: PanOptica, Inc.
    Inventors: David P. Bingaman, Paul G. Chaney, Martin B. Wax
  • OCULAR FORMULATIONS FOR DRUG-DELIVERY AND PROTECTION OF THE ANTERIOR SEGMENT OF THE EYE
    Publication number: 20180078531
    Abstract: The present application relates to topical formulations comprising Compound-I or its free base, and a second active agent selected from nicotinic acid, nicotinamide, and vitamin K, and a combination thereof, for treating ocular neovascularization. The present application also relates to pharmaceutical compositions comprising particles of Compound-I or its free base, and suspension formulations comprising the particle compositions of Compound-I or its free base.
    Type: Application
    Filed: September 28, 2017
    Publication date: March 22, 2018
    Inventors: David P. BINGAMAN, Paul G. CHANEY, Martin B. WAX
  • Ocular formulations for drug-delivery and protection of the anterior segment of the eye
    Patent number: 9814702
    Abstract: The present application relates to topical formulations comprising Compound-I or its free base, and a second active agent selected from nicotinic acid, nicotinamide, and vitamin K, and a combination thereof, for treating ocular neovascularization. The present application also relates to pharmaceutical compositions comprising particles of Compound-I or its free base, and suspension formulations comprising the particle compositions of Compound-I or its free base.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: November 14, 2017
    Assignee: PanOptica, Inc.
    Inventors: David P. Bingaman, Paul G. Chaney, Martin B. Wax
  • RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions
    Patent number: 9752147
    Abstract: RNA interference is provided for inhibition of connexin 43 (Cx43) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: September 5, 2017
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Jon E. Chatterton, Abbot F. Clark, Martin B. Wax
  • Ocular formulations for drug-delivery and protection of the anterior segment of the eye
    Patent number: 9623011
    Abstract: The present application relates to topical formulations comprising Compound-I or its free base, and a second active agent selected from nicotinic acid, nicotinamide, and vitamin K, and a combination thereof, for treating ocular neovascularization. The present application also relates to pharmaceutical compositions comprising particles of Compound-I or its free base, and suspension formulations comprising the particle compositions of Compound-I or its free base.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: April 18, 2017
    Assignee: PanOptica, Inc.
    Inventors: David P. Bingaman, Paul G. Chaney, Martin B. Wax
  • RNAi-MEDIATED INHIBITION OF CONNEXIN 43 FOR TREATMENT OF IOP-RELATED CONDITIONS
    Publication number: 20170009235
    Abstract: RNA interference is provided for inhibition of connexin 43 (Cx43) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.
    Type: Application
    Filed: September 27, 2016
    Publication date: January 12, 2017
    Inventors: Jon E. Chatterton, Abbot F. Clark, Martin B. Wax
  • OCULAR FORMULATIONS FOR DRUG-DELIVERY TO THE POSTERIOR SEGMENT OF THE EYE
    Publication number: 20160354349
    Abstract: The present invention relates to topical formulations comprising a compound of the following formula: for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w/v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and/or the choroid.
    Type: Application
    Filed: August 19, 2016
    Publication date: December 8, 2016
    Inventors: David P. Bingaman, Paul G. Chaney, Martin B. Wax
  • RNAi-Related Inhibition of TNF-alpha Signaling Pathway for Treatment of Ocular Angiogenesis
    Publication number: 20160326533
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.
    Type: Application
    Filed: July 25, 2016
    Publication date: November 10, 2016
    Inventors: Jon E. Chatterton, Abbot F. Clark, David P. Bingaman, Martin B. Wax, Adrian M. Timmers
  • RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions
    Patent number: 9476047
    Abstract: RNA interference is provided for inhibition of connexin 43 (Cx43) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: October 25, 2016
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Jon E. Chatterton, Abbot F. Clark, Martin B. Wax
  • Ocular formulations for drug-delivery to the posterior segment of the eye
    Patent number: 9446026
    Abstract: The present invention relates to topical formulations comprising a compound of the following formula: for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w/v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and/or the choroid.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 20, 2016
    Assignee: PanOptica, Inc.
    Inventors: David P. Bingaman, Paul G. Chaney, Martin B. Wax
  • RNAi-related inhibition of TNF-alpha signaling pathway for treatment of ocular angiogenesis
    Patent number: 9422556
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: August 23, 2016
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Jon E. Chatterton, Abbot F. Clark, David P. Bingaman, Martin B. Wax, Adrian M. Timmers
  • OCULAR FORMULATIONS FOR DRUG-DELIVERY AND PROTECTION OF THE ANTERIOR SEGMENT OF THE EYE
    Publication number: 20160206599
    Abstract: The present application relates to topical formulations comprising Compound-I or its free base, and a second active agent selected from nicotinic acid, nicotinamide, and vitamin K, and a combination thereof, for treating ocular neovascularization. The present application also relates to pharmaceutical compositions comprising particles of Compound-I or its free base, and suspension formulations comprising the particle compositions of Compound-I or its free base.
    Type: Application
    Filed: March 25, 2016
    Publication date: July 21, 2016
    Inventors: David P. Bingaman, Paul G. Chaney, Martin B. Wax